Copy number increase of HER-2 in colorectal cancers

Oncology Letters

Volumn 2, Issue 2, 2011, Pages 331-335

  Xiongiong, Yi ^a   Fang, Zhengyu ^a   Zhang, Chao ^a   Qi, Guolong ^d   Liu, Wenli ^a   Zhang, Wei ^b   Wan, Jun ^a,c  

^a Biomedical Research Institute   (China)

^b JINAN UNIVERSITY   (China)

^c HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

^d MEDICAL COLLEGE OF JINAN UNIVERSITY   (China)

Author keywords

Colorectal cancer; Copy number variations; HER 2

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MESSENGER RNA;

ADENOCARCINOMA; ARTICLE; BREAST CANCER; CANCER GROWTH; CHROMOSOME 17Q; COLORECTAL CANCER; CONTROLLED STUDY; COPY NUMBER VARIATION; DIAGNOSTIC VALUE; GENE LOCUS; GENE OVEREXPRESSION; GENETIC STABILITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION;

EID: 79551624868     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2010.225     Document Type: Article

References (28)

1. Schechter AL, Stern DF, Vaidyanathan L, et al: The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 312: 513-516, 1984.
2. Prenzel N, Fischer OM, Streit S, Hart S and Ullrich A: The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer 8: 11-31, 2001.
3. Siddiqa A, Long LM, Li L, Marciniak RA and Kazhdan I: Expression of HER-2 in MCF-7 breast cancer cells modulates anti-apoptotic proteins Survivin and Bcl-2 via the extracellular signal-related kinase (ERK) and phosphoinositide-3 kinase (PI3K) signalling pathways. BMC Cancer 8: 129, 2008.
4. Pohl M, Stricker I, Schoeneck A, et al: Antitumor activity of the HER2 dimerization inhibitor pertuzumab on human colon cancer cells in vitro and in vivo. J Cancer Res Clin Oncol 135: 1377-1386, 2009.
5. Al-Kuraya K, Novotny H, Bavi P, et al: HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer. J Clin Pathol 60: 768-772, 2007.
6. Herreros-Villanueva M, Rodrigo M, Claver M, et al: KRAS, BRAF, EGFR and HER2 gene status in a Spanish population of colorectal cancer. Mol Biol Rep: June, 2010 (E-pub ahead of print).
7. Yamashita H, Nishio M, Toyama T, et al: Coexistence of HER2 over-expression and p53 protein accumulation is a strong prog- nostic molecular marker in breast cancer. Breast Cancer Res 6: R24-R30, 2004.
8. Leonard DS, Hill AD, Kelly L, Dijkstra B, McDermott E and O'Higgins NJ: Anti-human epidermal growth factor receptor 2 monoclonal antibody therapy for breast cancer. Br J Surg 89: 262-271, 2002.
9. Sung JJ, Lau JY, Goh KL and Leung WK: Increasing incidence of colorectal cancer in Asia: implications for screening. Lancet Oncol 6: 871-876, 2005.
10. Lu JB, Sun XB, Dai DX, et al: Epidemiology of gastroentero- logy cancer in Henan Province, China. World J Gastroenterol 9: 2400-2403, 2003.
11. Lichtenstein P, Holm NV, Verkasalo PK, et al: Environmental and heritable factors in the causation of cancer - analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343: 78-85, 2000.
12. Andrews J, Kennette W, Pilon J, et al: Multi-platform whole- genome microarray analyses refine the epigenetic signature of breast cancer metastasis with gene expression and copy number. PLoS One 5: e8665, 2010.
13. Cho EK, Tchinda J, Freeman JL, Chung YJ, Cai WW and Lee C: Array-based comparative genomic hybridization and copy number variation in cancer research. Cytogenet Genome Res 115: 262-272, 2006.
14. Orsetti B, Courjal F, Cuny M, Rodriguez C and Theillet C: 17q21-q25 aberrations in breast cancer: combined allelotyping and CGH analysis reveals 5 regions of allelic imbalance among which two correspond to DNA amplification. Oncogene 18: 6262-6270, 1999.
15. Buness A, Kuner R, Ruschhaupt M, Poustka A, Sultmann H and Tresch A: Identification of aberrant chromosomal regions from gene expression microarray studies applied to human breast cancer. Bioinformatics 23: 2273-2280, 2007.
16. Yao J, Weremowicz S, Feng B, et al: Combined cDNA array comparative genomic hybridization and serial analysis of gene expression analysis of breast tumor progression. Cancer Res 66: 4065-4078, 2006.
17. Benusiglio PR, Pharoah PD, Smith PL, et al: HapMap-based study of the 17q21 ERBB2 amplicon in susceptibility to breast cancer. Br J Cancer 95: 1689-1695, 2006.
18. Dear PH: Copy-number variation: the end of the human genome? Trends Biotechnol 27: 448-454, 2009.
19. Shlien A, Tabori U, Marshall CR, et al: Excessive genomic DNA copy number variation in the Li-Fraumeni cancer predisposition syndrome. Proc Natl Acad Sci USA 105: 11264-11269, 2008.
20. Divne AM and Allen M: A DNA microarray system for forensic SNP analysis. Forensic Sci Int 154: 111-121, 2005.
21. Macconaill LE, Aldred MA, Lu X and Laframboise T: Toward accurate high-throughput SNP genotyping in the presence of inherited copy number variation. BMC Genomics 8: 211, 2007.
22. Gorringe KL and Campbell IG: High-resolution copy number arrays in cancer and the problem of normal genome copy number variation. Genes Chromosomes Cancer 47: 933-938, 2008.
23. Mitra A, Liu G and Song J: A genome-wide analysis of array- based comparative genomic hybridization (CGH) data to detect intra-species variations and evolutionary relationships. PLoS One 4: e7978, 2009.
24. Malan V, Chevallier S, Soler G, et al: Array-based comparative genomic hybridization identifies a high frequency of copy number variations in patients with syndromic overgrowth. Eur J Hum Genet 18: 227-232, 2010.
25. Dermitzakis ET and Stranger BE: Genetic variation in human gene expression. Mamm Genome 17: 503-508, 2006.
26. Guryev V, Saar K, Adamovic T, et al: Distribution and functional impact of DNA copy number variation in the rat. Nat Genet 40: 538-545, 2008.
27. Henrichsen CN, Vinckenbosch N, Zollner S, et al: Segmental copy number variation shapes tissue transcriptomes. Nat Genet 41: 424-429, 2009.
28. Sexton T, Umlauf D, Kurukuti S and Fraser P: The role of transcription factories in large-scale structure and dynamics of interphase chromatin. Semin Cell Dev Biol 18: 691-697, 2007.